EVA MARÍA
CIRUELOS GIL
Profesora asociada de Ciencias de la Salud
Tel Aviv University
Tel Aviv, IsraelPublicaciones en colaboración con investigadores/as de Tel Aviv University (3)
2022
-
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer
Annals of Oncology, Vol. 33, Núm. 12, pp. 1250-1268
2021
-
Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results from SOLAR-1
Annals of Oncology, Vol. 32, Núm. 2, pp. 208-217
2020
-
Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer
Annals of Oncology, Vol. 31, Núm. 8, pp. 1001-1010